HDL: The yin-yang of cardiovascular disease;HDL: O yin-yang da doença cardiovascular

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 9, 2010, Pages 777-784

  Leança, Camila Canteiro ^a   Passarelli, Marisa ^a   Nakandakare, Edna R ^a   Quintão, Eder C R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; HDL cholesterol; Reverse cholesterol transport; Tangier disease; Torcetrapib

Indexed keywords

EID: 79951975625     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000900002     Document Type: Article

References (44)

1. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8(6):737-41.
2. Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124:S11-20.
3. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764-72.
4. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98(11):1352-64.
5. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003;23(10):1881-8.
6. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221-32.
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22.
8. Lu Y, Dollé MET, Imholz S, Van't Slot R, Verschuren WMM, Wijmenga C, et al. Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations. J Lipid Res. 2008;49(12):2582-9.
9. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 2010;208(1):3-9.
10. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54(5):788-800.
11. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batist MC, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24(11):2181-7.
12. Mueller O, Chang E, Deng D, Franz T, Jing D, Kincaid R, et al. PROCAN study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med. 2008;46(4):490-8.
13. Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Relation of Gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular event in Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism. 2008;57(1):77-83.
14. Watanabe H, Söderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C. Decreased high-density lipoprotein (HDL) particle size, prebeta, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol. 2006;26(4):897-902.
15. Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21(4):305-11.
16. Forti N, Diament J. Apolipoproteínas B e A-I: fatores de risco cardiovascular? Rev Assoc Med Bras. 2007;53(3):276-82.
17. Van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apoliprotein A-I: significance for CV risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51(6):634-42.
18. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest. 2007;117(3):746-56.
19. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006;26(8):1702-11.
20. Siqueira AFA, Abdalla DSP, Ferreira SRG. LDL: da síndrome metabólica à instabilização da placa aterosclerótica. Arq Bras Endocrinol Metabol. 2006;50(2):334-43.
21. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Inter Med. 2008;263(3):256-73.
22. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res. 2010;51(6):1496-503.
23. Schwartz CC, Van den Broek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004;45(9):1594-607.
24. Quinet EM, Basso MD, Halpern AR, Yates DW, Sheffan RJ, Clerin V, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res. 2009;50(12):2358-70.
25. Vergeer M, Holleboom AG, Kastelein JJP, Kuivenhoven JA. The HDL hypothesis. Does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010;51(8):2058-73.
26. Fredrickson DS, Altrocchi PH, Avioli DS, Goodman DS, Goodman HC. Tangier disease: combined clinical staff conference at the National Institute of Health. Ann Intern Med. 1961;55:1016-31.
27. Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell Mol Life Sci. 2005;62(19-20):2150-60.
28. Chung S, Timmins JM, Duong M, Degiloramo C, Rong S, Sawyer JK, et al. Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. J Biol Chem. 2010;285(16):12197-209.
29. Schaefer EJ, Santos RD, Asztalos BF. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol. 2010;21(4):289-97.
30. Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimmer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem. 2007;282(8):5125-32.
31. Marchesi M, Sirtori CR. Therapeutic use of the high-density lipoprotein protein and peptides. Expert Opin Investig Drugs. 2006;15(3):227-41.
32. Hovingh GK, De Groot E, Van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16(2):139-45.
33. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009;120(7):628-35.
34. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50:S189-94.
35. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27(2):257-60.
36. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E, et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2010;121(3):366-74.
37. Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006;17(4):394-8.
38. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart R, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777-88.
39. Tsai MY, Johnson C, Kao WH, Sharrett AR, Arends VL, Kronmal R, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;200(2):359-67.
40. Quintão ECR, Cazita PM. Lipid transfer proteins: past, present and perspectives. Atherosclerosis. 2010;209(1):1-9.
41. Cazita PM, Barbeiro DF, Moretti AIS, Quintão ECR, Soriano FG. CETP expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock. 2008;30(5):590-5.
42. De Haan W, De Vries-van der Weij J, Van der Hoorn JW, Gautier T, Van der Hoogt CC, Westerterp M, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 2008;117(19):2515-22.
43. Nordestgaard BG, Benn M, Schnohr P. Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308.
44. Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524-32.